• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
  • Home
  • Science
  • Scientific Publications

Scientific Publications

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • Posters
  • Presentations
  • Publications
  • White Papers

20

Feb
2023

“CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial” published in “The Lancet Haematology”.

Read More

05

Oct
2022

Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy

Read More

25

Jan
2022

KEYNOTE-B79 Phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients

Read More

13

Dec
2021

Update from ASH: Data from CYAD-02 CYCLE 1 Phase 1 study and CYAD-211 IMMUNICY-1 Phase 1 study

Read More

13

Dec
2021

IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T-cell Therapy Platform

Read More

12

Nov
2021

Armoring NKG2D-based CAR T cells with IL-18 improves in vitro and in vivo anti-tumor activity

Read More

12

Nov
2021

Evolving Multiplexed shRNA to generate tailored CAR T cell therapy

Read More

12

Nov
2021

A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients

Read More

11

Jun
2021

Objective response at low dose in the first-in-human IMMUNICY-1 trial evaluating non-gene edited allogeneic CYAD-211 anti-BCMA CAR T product in relapsed or refractory multiple myeloma

Read More

11

Jun
2021

Update from EHA – Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in r/r MM

Read More

15

Jan
2021

ASCO GI: Updated Data from the alloSHRINK Phase 1 First-in-Human Study Evaluating CYAD-101, an Innovative Non-Gene-Edited Allogeneic CAR-T, in Metastatic Colorectal Cancer

Read More

24

Dec
2020

Hairpins and Scissors – Delivering a Non-Gene Edited Allogeneic CAR T Cell Therapy for the Masses

Read More

05

Dec
2020

ASH: Results from the Phase I Clinical Studies Evaluating CYAD-01, a first-generation NKG2D CAR T-cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Read More

05

Dec
2020

ASH: Clinical Development of a Non-Gene-Edited Allogeneic BCMA-Targeting CAR T-cell Product in Relapsed or Refractory Multiple Myeloma

Read More

05

Dec
2020

ASH: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating CYAD-02, an Optimized Non-Gene-Edited Engineered NKG2D CAR T-cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Read More

29

May
2020

ASCO: Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T-cells

Read More

29

May
2020

ASCO: CYAD-101, an innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy

Read More

10

Jan
2020

The integrated stress response promotes B7H6 expression

Read More

09

Dec
2019

Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Read More

09

Dec
2019

Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Read More

09

Dec
2019

Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo

Read More

09

Dec
2019

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

Read More

09

Nov
2019

Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Read More

09

Nov
2019

Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Read More

09

Nov
2019

Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

Read More

09

Nov
2019

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

Read More

16

Sep
2019

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

Read More

16

Sep
2019

Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

Read More

05

Jul
2019

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Read More

15

Jun
2019

DEVELOPMENT OF A NEXT GENERATION ALLOGENEIC CAR-T CELL PLATFORM WITHOUT GENE EDITING

Read More

15

Jun
2019

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Read More

15

Jun
2019

MODELING NKG2D-BASED CAR-T CELL THERAPY IN ANIMALS WITH ACUTE MYELOID LEUKEMIA

Read More

18

May
2019

NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

Read More

18

May
2019

NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

Read More

12

Dec
2018

Overcoming Target Driven Fratricide for T Cell Therapy

Read More

03

Dec
2018

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy Without a Prior Preconditioning Chemotherapy

Read More

03

Dec
2018

Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Read More

03

Dec
2018

Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Read More

03

Dec
2018

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Read More

18

Nov
2018

Pooling signaling and costimulatory domains in a flexible CARpool design

Read More

18

Nov
2018

Functional screening of different anti-B7H6 CAR designs

Read More

18

Nov
2018

Differential effects of target ligands upon NKG2D CAR T cell activation

Read More

18

Nov
2018

Overcoming target‐driven fratricide for CAR‐T cell therapy

Read More

18

Nov
2018

CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule

Read More

18

Nov
2018

Generating Allogeneic CAR T cells without Gene Editing

Read More

18

Nov
2018

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Read More

18

Nov
2018

Uncovering the phenotype, functional and homing properties of NKG2D CAR T cells

Read More

18

Nov
2018

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

Read More

09

Nov
2018

CYAD 101: A first non gene edited allogeneic CAR T cell

Read More

09

Nov
2018

Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors

Read More

19

Oct
2018

Tackling fratricide to manufacture clinical grade NKG2D‐CAR T cells for cancer therapy

Read More

19

Oct
2018

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Metastatic Colorectal Cancer

Read More

19

Oct
2018

The high expression of NKG2D ligands on tumor and non‐tumor cells and a lack of surface expression on healthy tissues provide a strong rationale to support NKG2D‐based therapeutic approaches for cancer.

Read More

01

Jul
2018

Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressingT cells for autologous adoptive cell therapy

Read More

19

May
2018

Early signs of clinical activity of NKG2D CAR-T cell (CYAD-01) activity in AML patient

Read More

16

May
2018

Expression of a TIM peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approach

Read More

16

May
2018

Overcoming target-driven fratricide for CAR-T cell therapy

Read More

16

May
2018

Functional screening of an anti-B7H6 specific chimeric antigen receptor (CAR)

Read More

27

Apr
2018

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient

Read More

17

Apr
2018

The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D Chimeric Antigen Receptor T cell therapy (CYAD-01) in acute myeloid leukemia

Read More

17

Apr
2018

NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

Read More

17

Apr
2018

A Phase 1 study assessing the safety and clinical activity of multiple doses of an NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer

Read More

17

Apr
2018

A Phase 1 study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer

Read More

04

Apr
2018

Celyad’s novel CAR T-cell therapy for solid malignancies

Read More

14

Nov
2017

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

Read More

01

Sep
2017

A Phase I Global Trial Targeting Multiple Solid and Hematologic Malignancies through a NKG2D receptor-based CAR-T Immunotherapy

Read More

01

Aug
2017

‘Atypical’ CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors

Read More

05

Jun
2017

A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

Read More

27

Mar
2017

CAR T NKR-2: Leveraging the Breadth of Innate Immunity

Read More

06

Dec
2016

Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Read More

13

Sep
2016

Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Read More

04

Jun
2016

A First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Read More
Learn About Celyad Oncology's Pipeline

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use